Novo Nordisk Adr (NVO)

Apr 04, 2026

Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight - The Motley Fool

Apr 04, 2026

Apr 04, 2026

Novo Nordisk Wegovy Subscription Targets Self Pay Demand And Investor Focus - Sahm

Apr 04, 2026

Apr 02, 2026

NVO Stock Price, Quote & Chart | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill

Apr 02, 2026

Mar 31, 2026

Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan - Sahm

Mar 31, 2026

Mar 30, 2026

Novo Nordisk (NYSE: NVO) details progress on DKK 15bn share repurchase - Stock Titan

Mar 30, 2026

Mar 30, 2026

Novo Nordisk A/S Stock: Pipeline Innovations Amid Share Price Pressures and Market Challenges - AD HOC NEWS

Mar 30, 2026

Mar 29, 2026

Novo Nordisk Voucher Win Meets Rising Scrutiny Of FDA Review Program - Sahm

Mar 29, 2026

Mar 28, 2026

Novo Nordisk A/S Stock: FDA Approval for Awiqli Bolsters Diabetes Portfolio Amid 2026 Market Recover - AD HOC NEWS

Mar 28, 2026

Mar 27, 2026

Novo Nordisk A/S Stock: Recent AGM Resolutions Reinforce Dual-Class Structure and Dividend Strength - AD HOC NEWS

Mar 27, 2026

Mar 26, 2026

NVO Stock Quote Price and Forecast - CNN

Mar 26, 2026

Mar 25, 2026

Novo Nordisk A/S stock faces pressure amid shifting obesity drug landscape and analyst hold rating - AD HOC NEWS

Mar 25, 2026

Mar 24, 2026

Novo Nordisk A/S stock faces analyst scrutiny amid Wegovy demand questions and Equal Weight rating h - AD HOC NEWS

Mar 24, 2026

Mar 22, 2026

Novo Nordisk A/S stock faces FDA warnings on GLP-1 drugs amid rising competition pressures - AD HOC NEWS

Mar 22, 2026

Mar 20, 2026

NVO Price History for Novo Nordisk A/S ADR Stock - Barchart.com

Mar 20, 2026

Mar 19, 2026

Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy - Sahm

Mar 19, 2026

Mar 18, 2026

Novo Nordisk A/S stock faces pressure from FDA warning on semaglutide reporting and Bernstein Underp - AD HOC NEWS

Mar 18, 2026

Mar 18, 2026

Novo Nordisk A/S stock faces headwinds from CagriSema trial setback amid buyback progress and compet - AD HOC NEWS

Mar 18, 2026

Mar 17, 2026

Novo Nordisk A/S stock rebounds on UBT251 trial data amid CEO turmoil and buyback momentum - AD HOC NEWS

Mar 17, 2026

Mar 16, 2026

Novo Nordisk A/S - GlobeNewswire Inc.

Mar 16, 2026

Mar 16, 2026

Novo Nordisk A/S Stock (ISIN: DK0062498333) Faces Headwinds from FDA Warning Amid GLP-1 Demand - AD HOC NEWS

Mar 16, 2026

Mar 15, 2026

Novo Nordisk A/S Stock Faces Brutal Choice: Can Oral Wegovy Rescue the Semaglutide Empire? - AD HOC NEWS

Mar 15, 2026

Mar 14, 2026

FDA Warning Tests Novo Nordisk Compliance And Reshapes NYSE NVO Risk Profile - Sahm

Mar 14, 2026

Mar 14, 2026

Novo Nordisk Telehealth Deal Weighs On Weak Share Price And Valuation - sahmcapital.com

Mar 14, 2026

Mar 12, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/SNVO - Finansavisen

Mar 12, 2026

Mar 10, 2026

Novo Nordisk A/S (NVO) Expands Manufacturing to Support Rising Global Demand for GLP-1 Drugs - Finviz

Mar 10, 2026

Mar 10, 2026

Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal - Finviz

Mar 10, 2026

Mar 10, 2026

Novo Nordisk 2026 Dividend Guide for UAE Investors - Bitget

Mar 10, 2026

Mar 09, 2026

Morgan Stanley Upgrades Novo Nordisk A/S (NVO) to Equal Weight From UnderweightHere's Why - Finviz

Mar 09, 2026